

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096366 A1

- (51) International Patent Classification⁷: **A61P 9/00**,
A61K 31/5386, 31/547, C07D 513/08, 498/08
- (74) Agent: **HOFMANN, Dieter**; Therwilerstrasse 87,
CH-4153 Reinach (CH).
- (21) International Application Number:
PCT/EP2004/004371
- (22) International Filing Date: 26 April 2004 (26.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/EP03/04492 30 April 2003 (30.04.2003) EP
- (71) Applicant (for all designated States except US): **ACTE-
LION PHARMACEUTICALS LTD** [CH/CH]; Gewerbe-
strasse 16, CH-4123 Allschwil (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BEZENCON,**
Oliver [CH/CH]; Dürrenmattweg 53, CH-4123 Allschwil
(CH). **BUR, Daniel** [CH/CH]; Im Rosengarten 24,
CH-4106 Therwil (CH). **FISCHLI, Walter** [CH/CH];
Obertorweg 64, CH-4123 Allschwil (CH). **REMEN,**
Lubos [CH/CH]; Kurzellängeweg 28, CH-4123 Allschwil
(CH). **RICHARD-BILDSTEIN, Sylvia** [FR/FR]; 12, rue
des Beaux Prés, F-68440 Dietwiller (FR). **WELLER,**
Thomas [CH/CH]; Hoelzlistrasse 32b, CH-4102 Bin-
ningen (CH). **SIFFERLEN, Thierry** [FR/FR]; 6, rue de
Thann, F-68116 Guewenheim (FR).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: 9-AZABICYCLO'3.3.1'NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN IN-
HIBITORS

(57) Abstract: The invention relates to novel 9-azabicyclo[3.3.1]nonene derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.



WO 2004/096366 A1

9-AZABICYCLO[3.3.1]NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS

5

The invention relates to novel compounds of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula I and especially their use as renin inhibitors in cardiovascular events and
10 renal insufficiency. Furthermore, these compounds can be regarded as inhibitors of other aspartyl proteases and might therefore be useful as inhibitors of plasmepsins to treat malaria and as inhibitors of *Candida albicans* secreted aspartyl proteases to treat fungal infections.

15 In the renin-angiotensin system (RAS) the biologically active angiotensin II (Ang II) is generated by a two-step mechanism. The highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT₁ and AT₂. Whereas
20 AT₁ seems to transmit most of the known functions of Ang II, the role of AT₂ is still unknown.

Modulation of the RAS represents a major advance in the treatment of cardiovascular diseases. ACE inhibitors and AT₁ blockers have been accepted to
25 treat hypertension (Waeber B. *et al.*, "The renin-angiotensin system: role in experimental and human hypertension", in Berkenhager W. H., Reid J. L. (eds): *Hypertension*, Amsterdam, Elsevier Science Publishing Co, 1996, 489-519; Weber M. A., *Am. J. Hypertens.*, 1992, 5, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. *et al.*, *Kidney International*, 1994, 45,
30 403; Breyer J. A. *et al.*, *Kidney International*, 1994, 45, S156), in the prevention of congestive heart failure (Vaughan D. E. *et al.*, *Cardiovasc. Res.*, 1994, 28, 159;

Fouad-Tarazi F. *et al.*, *Am. J. Med.*, **1988**, 84 (Suppl. 3A), 83) and myocardial infarction (Pfeffer M. A. *et al.*, *N. Engl. J. Med.*, **1992**, 327, 669).

The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D.,
5 *Cardiovasc. Drugs*, **1995**, 9, 645). The only substrate known for renin is
angiotensinogen, which can only be processed (under physiological conditions) by
renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be by-
passed by chymase, a serine protease (Husain A., *J. Hypertens.*, **1993**, 11, 1155).
In patients inhibition of ACE thus leads to bradykinin accumulation causing
10 cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%)
(Israili Z. H. *et al.*, *Annals of Internal Medicine*, **1992**, 117, 234). Chymase is not
inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in
patients treated with ACE inhibitors. Blockade of the AT₁ receptor (e.g. by
losartan) on the other hand overexposes other AT-receptor subtypes to Ang II,
15 whose concentration is dramatically increased by the blockade of AT₁ receptors.
This may raise serious questions regarding the safety and efficacy profile of AT₁
receptor antagonists. In summary, renin inhibitors are not only expected to be
different from ACE inhibitors and AT₁ blockers with regard to safety, but more
importantly also with regard to their efficacy to block the RAS.

20

Only limited clinical experience (Azizi M. *et al.*, *J. Hypertens.*, **1994**, 12, 419;
Neutel J. M. *et al.*, *Am. Heart*, **1991**, 122, 1094) has been created with renin
inhibitors because of their insufficient oral activity due to their peptidomimetic
character (Kleinert H. D., *Cardiovasc. Drugs*, **1995**, 9, 645). The clinical
25 development of several compounds has been stopped because of this problem
together with the high cost of goods. Only one compound containing four chiral
centers has entered clinical trials (Rahuel J. *et al.*, *Chem. Biol.*, **2000**, 7, 493;
Mealy N. E., *Drugs of the Future*, **2001**, 26, 1139). Thus, metabolically stable,
orally bioavailable and sufficiently soluble renin inhibitors that can be prepared on
30 a large scale are missing and sought. Recently, the first non-peptide renin
inhibitors were described which show high *in vitro* activity (Oefner C. *et al.*,
Chem. Biol., **1999**, 6, 127; Patent Application WO97/09311; Märki H. P. *et al.*, *Il*

Farmaco, 2001, 56, 21). However, the development status of these compounds is not known.


The present invention relates to the identification of renin inhibitors of a non-peptidic nature and of low molecular weight. Orally active renin inhibitors of long duration of action which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis are described.

10

The present invention describes non-peptidic renin inhibitors.

In particular, the present invention relates to novel compounds of the general formula I,

15



Formula I

wherein

20 X represents -O-; -S-; -SO-; -SO₂-;

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in *meta* or *para* position;

25 V represents a bond; -(CH₂)_r-; -A-(CH₂)_s-; -CH₂-A-(CH₂)_t-; -(CH₂)_s-A-; -(CH₂)₂-A-(CH₂)_u-; -A-(CH₂)_v-B-; -CH₂-CH₂-CH₂-A-CH₂-; -A-CH₂-CH₂-B-CH₂-; -CH₂-

A-CH₂-CH₂-B-; -CH₂-CH₂-CH₂-A-CH₂-CH₂-; -CH₂-CH₂-CH₂-CH₂-A-CH₂-; -A-CH₂-CH₂-B-CH₂-CH₂-; -CH₂-A-CH₂-CH₂-B-CH₂-; -CH₂-A-CH₂-CH₂-CH₂-B-; -CH₂-CH₂-A-CH₂-CH₂-B-; -O-CH₂-CH(OCH₃)-CH₂-O-; -O-CH₂-CH(CH₃)-CH₂-O-; -O-CH₂-CH(CF₃)-CH₂-O-; -O-CH₂-C(CH₃)₂-CH₂-O-; -O-CH₂-C(CH₃)₂-O-; -O-C(CH₃)₂-CH₂-O-; -O-CH₂-CH(CH₃)-O-; -O-CH(CH₃)-CH₂-O-; -O-CH₂-C(CH₂CH₂)-O-; or -O-C(CH₂CH₂)-CH₂-O-;

A and B independently represent -O-; -S-; -SO-; -SO₂;

10 U represents aryl; heteroaryl;

T represents -CONR¹-; -(CH₂)_pOCO-; -(CH₂)_pN(R¹)CO-; -(CH₂)_pN(R¹)SO₂-; or -COO-;

15 Q represents lower alkylene; lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl;

R¹ represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; cycloalkyl'- lower alkyl;

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

25 t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

v is the integer 2, 3, or 4;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

In the definitions of general formula I – if not otherwise stated – the term **lower alkyl**, alone or in combination with other groups, means saturated, straight and branched chain groups with one to seven carbon atoms, preferably one to four carbon atoms that can be optionally substituted by halogens. Examples of lower alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl. The methyl, ethyl and isopropyl groups are preferred.

10 The term **lower alkoxy** refers to a R-O group, wherein R is a lower alkyl. Examples of lower alkoxy groups are methoxy, ethoxy, propoxy, iso-propoxy, isobutoxy, sec-butoxy and tert-butoxy.

15 The term **lower alkenyl**, alone or in combination with other groups, means straight and branched chain groups comprising an olefinic bond and consisting of two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkenyl are vinyl, propenyl or butenyl.

20 The term **lower alkynyl**, alone or in combination with other groups, means straight and branched chain groups comprising a triple bond and consisting of two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkynyl are ethynyl, propynyl or butynyl.

25

The term **lower alkylene**, alone or in combination with other groups, means straight and branched divalent chain groups with one to seven carbon atoms, preferably one to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkylene are ethylene, propylene or butylene.

30

The term **lower alkenylene**, alone or in combination with other groups, means straight and branched divalent chain groups comprising an olefinic bond and

consisting of two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkenylene are vinylene, propenylene and butenylene.

- 5 The term **lower alkylenedioxy**, refers to a lower alkylene substituted at each end by an oxygen atom. Examples of lower alkylenedioxy groups are preferably methylenedioxy and ethylenedioxy.

- 10 The term **lower alkyleneoxy** refers to a lower alkylene substituted at one end by an oxygen atom. Examples of lower alkyleneoxy groups are preferably methyleneoxy, ethyleneoxy and propyleneoxy.

The term **halogen** means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine and bromine.

15

- The term **cycloalkyl** alone or in combination, means a saturated cyclic hydrocarbon ring system with 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which can be optionally mono- or multisubstituted by lower alkyl, lower alkenyl, lower alkenylene, lower alkoxy, 20 lower alkyleneoxy, lower alkylenedioxy, hydroxy, halogen, $-\text{CF}_3$, $-\text{NR}^1\text{R}^{1'}$, $-\text{NR}^1\text{C}(\text{O})\text{R}^{1'}$, $-\text{NR}^1\text{S}(\text{O}_2)\text{R}^{1'}$, $-\text{C}(\text{O})\text{NR}^1\text{R}^{1'}$, lower alkylcarbonyl, $-\text{COOR}^1$, $-\text{SR}^1$, $-\text{SOR}^1$, $-\text{SO}_2\text{R}^1$, $-\text{SO}_2\text{NR}^1\text{R}^{1'}$ whereby $\text{R}^{1'}$ represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; cycloalkyl - lower alkyl. The cyclopropyl group is a preferred group.

25

- The term **aryl**, alone or in combination, relates to the phenyl, the naphthyl or the indanyl group, preferably the phenyl group, which can be optionally mono- or multisubstituted by lower alkyl, lower alkenyl, lower alkynyl, lower alkenylene or lower alkylene forming with the aryl ring a five- or six-membered ring, lower 30 alkoxy, lower alkylenedioxy, lower alkyleneoxy, hydroxy, hydroxy-lower alkyl, halogen, cyano, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{NR}^1\text{R}^{1'}$, $-\text{NR}^1\text{R}^{1'}$ - lower alkyl, $-\text{NR}^1\text{C}(\text{O})\text{R}^{1'}$, $-\text{NR}^1\text{S}(\text{O}_2)\text{R}^{1'}$, $-\text{C}(\text{O})\text{NR}^1\text{R}^{1'}$, $-\text{NO}_2$, lower alkylcarbonyl, $-\text{COOR}^1$, $-\text{SR}^1$, $-\text{SOR}^1$,

-SO₂R¹, -SO₂NR¹R^{1'}, benzyloxy, whereby R^{1'} has the meaning given above. Preferred substituents are halogen, lower alkoxy, lower alkyl, CF₃, OCF₃.

The term **aryloxy** refers to an Ar-O group, wherein Ar is an aryl. An example of
5 a lower aryloxy group is phenoxy.

The term **heterocyclyl**, alone or in combination, means saturated or unsaturated (but not aromatic) five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which
10 rings can be optionally substituted with lower alkyl, hydroxy, lower alkoxy and halogen. The nitrogen atoms, if present, can be substituted by a -COOR² group. Examples of such rings are piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, imidazolidinyl, dihydropyrazolyl,
15 pyrazolidinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl.

The term **heteroaryl**, alone or in combination, means six-membered aromatic rings containing one to four nitrogen atoms; benzofused six-membered aromatic rings containing one to three nitrogen atoms; five-membered aromatic rings
20 containing one oxygen, one nitrogen or one sulfur atom; benzofused five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; five-membered aromatic rings containing one oxygen and one nitrogen atom and benzofused derivatives thereof; five-membered aromatic rings containing a sulfur and a nitrogen or an oxygen atom and benzofused derivatives thereof; five-
25 membered aromatic rings containing two nitrogen atoms and benzofused derivatives thereof; five-membered aromatic rings containing three nitrogen atoms and benzofused derivatives thereof, or a tetrazolyl ring. Examples of such ring systems are furanyl, thiophenyl, pyrrolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl,
30 pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, coumarinyl, benzothiophenyl, quinazolinyl, quinoxalinyl. Such rings may be adequately substituted with lower alkyl, lower alkenyl, lower alkynyl, lower alkylene, lower alkenylene, lower

alkylenedioxy, lower alkyleneoxy, hydroxy-lower alkyl, lower alkoxy, hydroxy, halogen, cyano, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{NR}^1\text{R}^{1'}$, $-\text{NR}^1\text{R}^{1'}$ - lower alkyl, $-\text{N}(\text{R}^1)\text{COR}^1$, $-\text{N}(\text{R}^1)\text{SO}_2\text{R}^1$, $-\text{CONR}^1\text{R}^{1'}$, $-\text{NO}_2$, lower alkylcarbonyl, $-\text{COOR}^1$, $-\text{SR}^1$, $-\text{SOR}^1$, $-\text{SO}_2\text{R}^1$, $-\text{SO}_2\text{NR}^1\text{R}^{1'}$, another aryl, another heteroaryl or another heterocyclyl and
5 the like, whereby $\text{R}^{1'}$ has the meaning given above. Preferred heteroaryl are pyridinyl, pirimidinyl, pirazinyl.

The term **heteroaryloxy** refers to a Het-O group, wherein Het is a heteroaryl.

10 The expression **pharmaceutically acceptable** salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms or in case the compound of formula I is acidic in
15 nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.

Compounds of the invention also include nitrosated compounds of the general formula I that have been nitrosated through one or more sites such as oxygen
20 (hydroxyl condensation), sulfur (sulffiydryl condensation) and/or nitrogen. The nitrosated compounds of the present invention can be prepared using conventional methods known to one skilled in the art. For example, known methods for nitrosating compounds are described in U.S. Pat. Nos. 5,380,758 and 5,703,073; WO 97/27749; WO 98/19672; WO 98/21193; WO 99/00361 and Oae et al, Org.
25 Prep. Proc. Int., 15(3): 165-198 (1983), the disclosures of each of which are incorporated by reference herein in their entirety.

The compounds of the general formula I can contain two or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers,
30 mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form and pharmaceutically acceptable salts thereof.

The present invention encompasses all these forms. Mixtures may be separated in a manner known *per se*, i.e. by column chromatography, thin layer chromatography, HPLC or crystallization.

- 5 A group of preferred compounds of general formula I above are those wherein X, W, V, and U are as defined in general formula I and

T is -CONR¹-;

Q is methylene;

- 10 M is aryl; or heteroaryl.

Another group of even more preferred compounds of general formula I are those wherein X, W, U, T, Q, and M are as defined in general formula I above and

V is -CH₂CH₂O-; -CH₂CH₂CH₂O-; -OCH₂CH₂O-.

15

Another group of also more preferred compounds of general formula I are those wherein V, U, T, Q, and M are as defined in general formula I above and

W represents a 1,4-disubstituted phenyl group.

20

Another group of also more preferred compounds of general formula I are those wherein X, W, V, U, T, Q, and M are as defined in general formula I above and

- 25 U is a mono-, di-, or trisubstituted phenyl or heteroaryl, wherein the substituents are halogen, lower alkyl, lower alkoxy, CF₃.

Especially preferred compounds of general formula I are those selected from the group consisting of:

- 30 (*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3 λ ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide,

5

(*rac.*)-(1*R**, 3*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3 λ ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

10 (*rac.*)-(1*R**, 3*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3 λ ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide,

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide, and

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3 λ ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.

The compounds of general formula I and their pharmaceutically acceptable salts may be used as therapeutics e.g. in form of pharmaceutical compositions. These pharmaceutical compositions containing at least one compound of general formula

25 I and usual carrier materials and adjuvants may especially be used for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin angiotensin system (RAS), comprising cardiovascular and renal diseases. Examples of such diseases are hypertension, coronary diseases, cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal

30 failure. They can also be used to prevent restenosis after balloon or stent angioplasty, to treat erectile dysfunction, glomerulonephritis, renal colic, and glaucoma. Furthermore, they can be used in the therapy and the prophylaxis of

diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, as well as other diseases presently known to be related to the RAS.

- 5 In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are related to the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications,
- 10 complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases which are related to the RAS, which method comprises administering a compound according to general formula I to a human being or animal.
- 15 The invention further relates to the use of compounds of general formula I for the treatment or prophylaxis of diseases which are associated with the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic,
- 20 glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.

The compounds of formula I may also be used in combination with one or more other pharmacologically active compounds e. g. with other renin inhibitors, with ACE-inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists, alpha-adrenergic antagonists, and neutral endopeptidase inhibitors, for the treatment of disorders as above-mentioned


All forms of prodrugs leading to an active component comprised by general formula I above are included in the present invention.

The compounds of general formula I can be manufactured by the methods outlined below, by the methods described in the examples or by analogous methods.

Chemistry

Bicyclic systems of type A (Scheme 1; Jerchel, D; *et al.*; *Justus Liebigs Ann. Chem.*, **1957**, 607, 126; Zirkle, C. L.; *et al.*; *J. Org. Chem.*, **1961**, 26, 395) can be used as starting material. A stereoselective or a racemic acylation (Majewski, M; *et al.*; *J. Org. Chem.*, **1995**, 60, 5825) may yield a bicyclic compound of type B. R^c can typically be a methyl, an ethyl, or a benzyl substituent. These compounds can be then converted into the corresponding vinyl triflates C, then a carbon-carbon coupling, typically catalyzed by a Pd-complex, can lead to a derivative of type D. R^a optionally represents any chemical precursor of a U-V group as defined in general formula I. Protecting group manipulation can lead to a bicyclic system of type E, and standard manipulations, like deprotection and *Mitsunobu* coupling, can lead to bicyclic compounds of type F. Hydrolysis of the ester can lead to compounds of type G, then an amide coupling for instance to bicyclic compounds of type H. If X¹ is a sulfur atom, it can be oxidized to a sulfoxide or a sulfone at almost any stage of the process. Then deprotection can lead to the final compounds. The chemistry described in earlier patent applications, for instance in WO 03/093267 or WO 04/002957, can be used as well.

Scheme 1



5

The compounds of formula I and their pharmaceutically acceptable acid addition salts can be used as medicaments, e. g. in the form of pharmaceutical preparations for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e. g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e. g. in the

10

form of suppositories, parenterally, e. g. in the form of injection solutions or infusion solutions, or topically, e. g. in the form of ointments, creams or oils.

The production of pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable acid addition salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1
5 mg to about 1000 mg, especially about 50 mg to about 500 mg, comes into consideration.

The pharmaceutical preparations conveniently contain about 1 - 500 mg, preferably 5 - 200 mg of a compound of formula I.

10

The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

Examples

15

Abbreviations

	ACE	Angiotensin Converting Enzyme
	Ang	Angiotensin
20	aq.	aqueous
	Boc	<i>tert</i> -Butyloxycarbonyl
	BSA	Bovine serum albumine
	BuLi	<i>n</i> -Butyllithium
	DIPEA	Diisopropylethylamine
25	DMAP	4- <i>N,N</i> -Dimethylaminopyridine
	DMSO	Dimethylsulfoxide
	EDC·HCl	Ethyl- <i>N,N</i> -dimethylaminopropylcarbodiimide hydrochloride
	EIA	Enzyme immunoassay
	Et	Ethyl
30	EtOAc	Ethyl acetate
	FC	Flash Chromatography
	HOBt	Hydroxybenzotriazol

	LDA	Lithium diisopropyl amide
	MCPBA	<i>meta</i> -Chloroperbenzoic acid
	MeOH	Methanol
	org.	organic
5	PG	protecting group
	Ph	Phenyl
	RAS	Renin Angiotensin System
	RP18	Reversed phase column, filled with C ₁₈ hydrocarbon
	rt	room temperature
10	sol.	Solution
	TBDMS	<i>tert</i> -Butyldimethylsilyl
	Tf	Trifluoromethylsulfonyl
	THF	Tetrahydrofuran

15 **Preparation of cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amine**

a) 2-Chloro-3,*N*-dimethyl-*N*-phenylisonicotinamide

To the sol. of 2-chloro-*N*-phenylisonicotinamide (Epszajn, J.; Bieniek, A.; Plotka, M. W.; Suwald, K., *Tetrahedron*, **1989**, *45*, 7469, 139.8 g, 601 mmol) in THF (1
20 L) was added at -78 °C BuLi (1.6 M in hexane, 826 mL, 1321 mmol) over 2 h, while the temperature of reaction mixture was kept below -65°C. The mixture was then stirred for 30 min. at this temperature. Methyl iodide (123 mL, 1.98 mol) was added and the mixture was stirred for 1 h at -78 °C. The mixture was allowed to warmed up slowly to 33 °C and stirred at this temperature for 30 min.
25 Water (300 mL) was added dropwise, then aq. 10% NH₄OH (300 mL) was added, and the mixture was extracted with ether (3 x 300 mL). The combined org. phases were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the product as pale yellow amorphous material (124.92 g, 80%).

30 b) 2-Chloro-3-methylpyridine-4-carbaldehyde

To a sol. of 2-chloro-3,*N*-dimethyl-*N*-phenylisonicotinamide (124.9 g, 479 mmol) in CH₂Cl₂ (1300 mL) was added at -78 °C DIBAL (1M in THF, 719 mL, 719

mmol) over 1 h, and the mixture was stirred then for 2 h at this temperature. DIBAL (1M in THF, 281 mL, 281 mmol) was added again, and the reaction mixture was stirred at -60 °C for 30 min. Aq. sat. potassium sodium tartrate (500 mL) was added over 30 min, the cooling bath was removed, and the mixture was stirred overnight at rt. Water was added (100 mL), the org. phase was separated, and the water phase was extracted with CH₂Cl₂ (2x100 mL). The combined org. phase were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the product (58.35 g, 78%) as pale yellow crystals.

10 c) (2-Chloro-3-methylpyridin-4-ylmethyl)cyclopropylamine

A mixture of 2-chloro-3-methylpyridine-4-carbaldehyde (58.35 g, 375 mmol) and cyclopropylamine (52.6 mL, 750 mmol) in MeOH (800 mL) was stirred overnight at rt. The mixture was cooled to 0 °C and NaBH₄ (18.4 g, 488 mmol) was added portionwise. The mixture was stirred overnight at rt. Aq. 1M NaOH (250 mL) was added and the solvents were partially removed under reduced pressure. The aq. phase was extracted with EtOAc (3x). The combined org. phases were washed with aq. sat. NaCl, dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the compound (54.56 g, 74%) as a pale yellow liquid.

20 d) Cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amine

A mixture of (2-chloro-3-methylpyridin-4-ylmethyl)cyclopropylamine (10.0 g, 50.8 mmol) and sodium methoxide (13.73g, 254 mmol) in dioxan (40 mL) was heated to reflux for 48 h. The reaction mixture was filtered through *Celite*, and the remaining solid was washed with ether (2x). The solvents were removed under reduced pressure. Purification by FC yielded the title compound (8.8 g, 90%) as a pale yellow liquid.

Preparation of {2-[3-(*tert*-Butyldimethylsilyloxy)propoxy]-3-methylpyridin-4-ylmethyl}cyclopropylamine

30

To a sol. of NaH (55%, 4.97 g, 114 mmol) in toluene was added dropwise 3-(*tert*-butyldimethylsilyloxy)propan-1-ol (20.1 g, 42.6 mmol) at 0 °C. The mixture

was stirred for 1 h at rt and (2-chloro-3-methylpyridin-4-ylmethyl)-cyclopropylamine (16.0 g, 81.3 mmol) was added. The mixture was heated to reflux overnight, and allowed to cool to rt. The solvents were removed under reduced pressure. The residue was diluted with Et₂O, and washed with water (2x).
5 The combined aq. extracts were extracted back with Et₂O (2x). The combined org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound (7.56 g, 26%) as a pale yellow liquid.

10 Precursors

(rac.)-(1R*, 5S*)-9-Methyl-7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-6-carboxylic acid methyl ester (B1)

15 A mixture of NaH (0.91 g, 60% in oil, 21 mmol) and dimethylcarbonate (2.18 g, 24 mmol) in cyclohexane (16 mL) was heated to 60 °C under nitrogen. 9-Methyl-7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane A1 (1.55 g, 10.0 mmol) was added, and the mixture was stirred at reflux for 2 h. The mixture was allowed to cool to rt, and ice and water were added. The phases were separated, and the org. phase was
20 washed with water (1x). The combined aq. extracts were saturated with NH₄Cl, and extracted back with CHCl₃. The combined org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (1.02 g, 48%).

25 (rac.)-(1R*, 5S*)-9-Methyl-7-oxo-3-thia-9-azabicyclo[3.3.1]nonane-6-carboxylic acid methyl ester (B2)

A sol. of LDA was prepared from diisopropylamine (5.8 mL, 41.2 mmol), BuLi (1.6 M in hexanes, 26.2 mL, 42.0 mmol) and THF (60 mL). This sol. was cooled
30 to -78 °C and a sol. of 9-methyl-3-thia-9-azabicyclo[3.3.1]nonan-7-one A2 (6.42 g, 37.5 mmol) in THF (70 mL) was added dropwise over 3 min. The reaction mixture was stirred for 3 h at -78 °C, then methylcyanoformat (3.87 mL, 48.9

mmol) was added. The reaction mixture was stirred for 1 h at -78 °C and a sol. of AgNO₃ (9.12 g, 53.7 mmol) in H₂O/THF (1:1, 70 mL) was added. After 10 min, H₂O (35 mL) and AcOH (35 mL) were added and the reaction mixture was allowed to warm to rt. Ammoniac (25% in water, 120 mL) was added. The reaction mixture was extracted with CH₂Cl₂ (2x). The combined org. extracts were dried over MgSO₄ and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (7.59 g, 88%).

(rac.)-(1R*, 5S*)-9-Methyl-7-trifluoromethanesulfonyloxy-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (C1)

A sol. of bicyclononanone B1 (4.67 g, 21.9 mmol) in THF (100 mL) was cooled to 0 °C and NaH (about 60% in mineral oil, 1.13 g, about 26 mmol) was added. A gas evolution was observed. After 20 min, Tf₂NPh (10.0 g, 28 mmol) was added. 10 min later, the ice bath was removed. The sol. was stirred overnight, and diluted with EtOAc and washed with brine (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound as an oil (6.11 g, 81%).

(rac.)-(1R*, 5S*)-9-Methyl-7-trifluoromethanesulfonyloxy-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (C2)

A sol. of bicyclononanone B2 (550 mg, 2.40 mmol) in THF (10 mL) was cooled to 0 °C and NaH (about 60% in mineral oil, 144 mg, about 3.60 mmol) was added. A gas evolution was observed. After 20 min, Tf₂NPh (1.11 g, 3.12 mmol) was added. 10 min later, the ice bath was removed. The sol. was stirred overnight, and diluted with EtOAc and washed with brine (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound as an oil (667, 77%).

(rac.)-(1R*, 5S*)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-9-methyl-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (D1)

5 A sol. of [3-(4-bromophenyl)propoxy]-*tert*-butyldimethylsilane (Kiesewetter D. O., *Tetrahedron Asymmetry*, 1993, 4, 2183, 9.88 g, 30.0 mmol) in THF (200 mL) was cooled to -78 °C. BuLi (1.6M in hexane, 18.7 mL, 30.0 mmol) was added. After 30 min, ZnCl₂ (1M in THF, 30 mL, 30 mmol, prepared from ZnCl₂ dried overnight at 150 °C and THF) was added. The mixture was allowed to warm up
10 to rt. Vinyl triflate C1 (5.87 g, 17.0 mmol) in THF (30 mL) and then Pd(PPh₃)₄ (390 mg, 0.34 mmol) were added. The mixture was heated TO 40 °C for 30 min and aq. 1M HCl (1 mL) was added. The mixture was diluted with EtOAc and washed with aq. 1M NaOH (1x). The org. extracts were dried over MgSO₄, filtered and the solvents were removed under reduced pressure. Purification of the
15 residue by FC yielded the title product (5.87 g, 77%).

(rac.)-(1R*, 5S*)-7-{4-[3-(*tert*-Butyldimethylsilyloxy)propyl]phenyl}-9-methyl-3-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid methyl ester (D2)

20

A sol. of [3-(4-bromophenyl)propoxy]-*tert*-butyldimethylsilane (Kiesewetter D. O., *Tetrahedron Asymmetry*, 1993, 4, 2183, 1.52 g, 4.61 mmol) in THF (20 mL) was cooled to -78 °C. BuLi (1.6M in hexane, 2.88 mL, 4.61 mmol) was added. After 30 min, ZnCl₂ (1M in THF, 5.00 mL, 5.00 mmol, prepared from ZnCl₂ dried
25 overnight at 150 °C and THF) was added. The mixture was allowed to warm up to rt. Vinyl triflate C2 (667 mg, 1.85 mmol) in THF (20 mL) and then Pd(PPh₃)₄ (107 mg, 0.093 mmol) were added. The mixture was heated to 50 °C for 30 min and aq. 1M HCl (1 mL) was added. The mixture was diluted with EtOAc and washed with aq. 1M NaOH (1x). The org. extracts were dried over MgSO₄,
30 filtered and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title product (818 mg, 96%).

(rac.)-(1*R, 5*S**)-7-[4-(3-Hydroxypropyl)phenyl]-3-oxa-9-azabicyclo[3.3.1]-non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E1)**

1-Chloroethyl chloroformate (5.90 g, 41 mmol) was added to a sol. of
5 bicyclononene **D1** (5.72 g, 12.8 mmol) in 1,2-dichloroethane (75 mL). The sol.
was heated to reflux. After 4 h, the reaction mixture was allowed to cool to rt, and
the solvents were removed under reduced pressure. The residue was diluted with
MeOH (50 mL), and the mixture was stirred for 20 min at rt, then for 45 min at 80
°C. The solvents were removed under reduced pressure, and the residue was
10 diluted with CHCl₃. This mixture was washed with aq. 1 M NaOH (1x), and brine
(1x). The combined aq. extracts were extracted back with CHCl₃ (2x). The
combined org. extracts were dried over MgSO₄, filtered, and the solvents were
removed under reduced pressure. The residue was dissolved in CH₂Cl₂ (60 mL),
DIPEA (3.18 g, 24.6 mmol) was added, and the mixture was cooled to 0 °C.
15 Boc₂O (3.14 g, 14.4 mmol) was added and the mixture was stirred at 0 °C for 1 h,
then at rt for 2 h. The mixture was washed with aq. 1M HCl (1x), and aq. sat.
NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the
solvents were removed under reduced pressure. Purification of the residue by FC
yielded the title compound (4.17 g, 78%).

20

(rac.)-(1*R, 5*S**)-7-[4-(3-Hydroxypropyl)phenyl]-3-thia-9-azabicyclo[3.3.1]-non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E2)**

1-Chloroethyl chloroformate (1.93 mL, 17.7 mmol) was added to a sol. of
25 bicyclononene **D2** (818 mg, 1.77 mmol) and NaHCO₃ (1.49 g, 17.7 mmol) in 1,2-
dichloroethane (20 mL). The sol. was heated to reflux. After 3 h, the reaction
mixture was allowed to cool to rt, filtered, and the solvents were thoroughly
removed under reduced pressure. MeOH (20 mL) was added and mixture was
stirred at 60 °C for 20 min. The mixture was allowed to cool to rt and the
30 solvents were removed under reduced pressure. The residue was dissolved in
CH₂Cl₂ (20 mL), DIPEA (1.82 mL, 10.6 mmol) was added, and the mixture was
cooled to 0 °C. Boc₂O (1.16 g, 5.31 mmol) was added and the mixture was stirred

at 0 °C for 30 min, then at rt for 30 min. The mixture was washed with aq. 1M HCl (1x), and aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (586 mg, 76%).

5

(rac.)-(1*R, 5*S**)-7-[4-(2-Hydroxyethyl)phenyl]-3,3-dioxo-3λ⁶-thia-9-aza-bicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E3)**

- 10 A sol. of compound E2 (586 mg, 1.35 mmol) in CH₂Cl₂ (15 mL) was cooled to 0 °C and 3-chloroperbenzoic acid (70%, 359 mg, 2.97 mmol) was added. The mixture was stirred at rt for 2 h and 3-chloroperbenzoic acid (70%, 359 mg, 2.97 mmol) was added again. The mixture was stirred again for 2 h and was diluted with more CH₂Cl₂. The mixture was washed with aq. sat. NaHCO₃ (1x). The org.
15 extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (578 mg, 92%).

- (rac.)-(1*R**, 3*R**, 5*S**)-7-[4-(2-Hydroxyethyl)phenyl]-3-oxo-3λ⁴-thia-9-aza-bicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (E4)**
- 20

- A sol. of compound E2 (0.82 g, 1.89 mmol) in CH₂Cl₂ (21 mL) was cooled to 0 °C and MCPBA (70%, 233 mg, 0.945 mmol) was added. The mixture was stirred
25 at 0 °C for 15 min. MCPBA (197 mg, 0.880 mmol) was added again. The mixture was stirred for 15 min at rt, and was diluted with more CH₂Cl₂. The mixture was washed with aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (1.51 g., 89%).

30

(rac.)-(1*R, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (F1)**

- 5 Tributylphosphine (7.05 g, 30.0 mmol) was added to a sol. of bicyclononene E2 (4.04 g, 9.7 mmol), 2-chloro-3,6-difluorophenol (2.89 g, 17.5 mmol) and azodicarboxylic dipiperidide (7.05 g, 30.0 mmol) in toluene (80 mL). The mixture was heated to reflux for 2 h and allowed to cool to rt. The solvents were removed under reduced pressure. Purification by FC yielded the title compound
10 (4.60 g, 84%).

(rac.)-(1*R, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-3,3-dioxo-3 λ ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester 6-methyl ester (F2)**

- 15 Tributylphosphine (85%, 1.08 mL, 3.72 mmol) was added to a sol. of bicyclononene E3 (578 mg, 1.24 mmol), 2-chloro-3,6-difluorophenol (407 mg, 2.48 mmol) and azodicarboxylic dipiperidide (626 mg, 2.48 mmol) in toluene (10 mL). The mixture was heated to reflux for 2 h and allowed to cool to rt. The
20 solvents were removed under reduced pressure. Purification by FC yielded the title compound (668 mg, 88%).

- (rac.)-(1*R**, 3*R**, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-3,3-dioxo-3 λ ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-
25 butyl ester 6-methyl ester (F3)**

- Tributylphosphine (85%, 3.30 mL, 11.3 mmol) was added to a sol. of bicyclononene E4 (1.70 mg, 3.78 mmol), 2-chloro-3,6-difluorophenol (930 mg, 5.67 mmol) and azodicarboxylic dipiperidide (1.90 g, 7.26 mmol) in toluene (45
30 mL). The mixture was heated to reflux for 1 h and allowed to cool to rt. The solvents were removed under reduced pressure. Purification by FC yielded the title compound (1.94 g, 86%).

(rac.)-(1*R, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester (G1)**

Bicyclononene **F1** (4.60 g, 25 mmol) was dissolved in EtOH (200 mL). Aq. 1M NaOH (200 mL) was added and the mixture was heated to 80 °C. The sol. was stirred for 5 h at 80 °C, then allowed to cool down to rt. After acidification to pH = 1-2 with aq. 1M HCl the mixture was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO₄, filtered and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (4.50 g, quantitative).

(rac.)-(1*R, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester (G2)**

Bicyclononene **F2** (668 mg, 1.09 mmol) was dissolved in EtOH (7 mL). Aq. 1M NaOH (3 mL) was added and the mixture was heated to 80 °C. The sol. was stirred for 5 h at 80 °C, then allowed to cool down to rt. After acidification to pH = 1-2 with aq. 1M HCl the mixture was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO₄, filtered and the solvents were removed under reduced pressure. The residue was used further without purification (624 mg, 96%).

(rac.)-(1*R, 3*R**, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6,9-dicarboxylic acid 9-*tert*-butyl ester (G3)**

Bicyclononene **F3** (1.94 g, 3.25 mmol) was dissolved in EtOH (24 mL). Aq. 1M NaOH (10 mL) was added and the mixture was heated to 80 °C. The sol. was stirred for 1 h at 80 °C, then allowed to cool down to rt. After acidification to pH = 1-2 with aq. 1M HCl the mixture was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO₄, filtered and the solvents were

removed under reduced pressure. The residue was used further without purification (1.86 g, 98%).

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-6-
5 [cyclopropyl-(3-methoxy-2-methylbenzyl)carbamoyl]-3-oxa-9-azabicyclo-
[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H1)

A mixture of bicyclononene G1 (360 mg, 2.0 mmol), cyclopropyl-(3-methoxy-2-methylbenzyl)amine (prepared by reductive amination from 3-methoxy-2-methylbenzaldehyde, Comins, D. L.; Brown, J. D., *J. Org. Chem.*, 1989, 54, 3730,
10 and cyclopropylamine; 1.05 g, 6.00 mmol), DIPEA (1.37 mL, 8.00 mmol), DMAP (61 mg, 0.50 mmol), HOBt (149 mg, 1.10 mmol) and EDC·HCl (1.19 g, 6.00 mmol) in CH₂Cl₂ (10 mL) was stirred at rt for 3 days. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃ (1x).
15 The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (260 mg, 55%).

(*rac.*)-(1*R**, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-6-
20 [cyclopropyl-(2,3-dichlorobenzyl)carbamoyl]-3,3-dioxo-3λ⁶-thia-9-azabicyclo-
[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H2)

A mixture of bicyclononene G2 (624 mg, 1.04 mmol), cyclopropyl-(2,3-dichlorobenzyl)amine (676 mg, 3.13 mmol), DIPEA (0.712 mL, 4.16 mmol), DMAP (32
25 mg, 0.25 mmol), HOBt (169 mg, 1.25 mmol) and EDC·HCl (498 mg, 2.60 mmol) in CH₂Cl₂ (10 mL) was stirred at rt overnight. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

(rac.)-(1*R, 3*R**, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-6-[cyclopropyl-(3-methoxy-2-methylbenzyl)carbamoyl]-3-oxo-3 λ^4 -thia-9-aza-bicyclo-[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H3)**

5 A mixture of bicyclononene G3 (150 mg, 0.257 mmol), cyclopropyl-(3-methoxy-2-methylbenzyl)amine (prepared by reductive amination from 3-methoxy-2-methylbenzaldehyde, Comins, D. L.; Brown, J. D., *J. Org. Chem.*, **1989**, *54*, 3730, and cyclopropylamine; 148 mg, 0.771 mmol), DIPEA (0.180 mL, 1.02 mmol), DMAP (8 mg, 0.06 mmol), HOBt (52 mg, 0.38 mmol) and EDC·HCl (123 mg,
10 0.642 mmol) in CH₂Cl₂ (10 mL) was stirred at rt for 2 days. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (183 mg, 94%).

15

(rac.)-(1*R, 3*R**, 5*S**)-7-{4-[2-(2-Chloro-3,6-difluorophenoxy)ethyl]phenyl}-6-[cyclopropyl-(3-methoxy-2-methylpyridin-4-ylmethyl)carbamoyl]-3-oxo-3 λ^4 -thia-9-aza-bicyclo-[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H4)**

20 A mixture of bicyclononene G3 (150 mg, 0.257 mmol), cyclopropyl-(3-methoxy-2-methylpyridin-4-ylmethyl)amine (149 mg, 0.773 mmol), DIPEA (0.180 mL, 1.02 mmol), DMAP (8 mg, 0.06 mmol), HOBt (52 mg, 0.38 mmol) and EDC·HCl (123 mg, 0.642 mmol) in CH₂Cl₂ (10 mL) was stirred at rt for 2 days. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃
25 (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (180 mg, 93%).

(rac.)-(1*R, 3*R**, 5*S**)-6-({2-[3-(*tert*-Butyldimethylsilyloxy)propoxy]-3-methylpyridin-4-ylmethyl}cyclopropylcarbamoyl)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-aza-bicyclo[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H5)**

30

A mixture of bicyclononene **G1** (2.05 g, 3.72 mmol), {2-[3-(*tert*-butyldimethylsilyloxy)propoxy]-3-methyl-pyridin-4-ylmethyl}cyclopropyl-amine (1.96, 5.59 mmol), DIPEA (2.55 mL, 14.9 mmol), DMAP (114 mg, 0.93 mmol), HOBt (757 mg, 5.59 mmol) and EDC·HCl (2.51 g, 13 mmol) in CH₂Cl₂ (50 mL) was stirred at rt overnight. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (3.00 g, 91%).

10

(rac.)-(1*R, 3*R**, 5*S**)-6-({2-[3-(*tert*-Butyldimethylsilyloxy)propoxy]-3-methylpyridin-4-ylmethyl}cyclopropylcarbamoyl)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-9-carboxylic acid *tert*-butyl ester (H6)**

15

A mixture of bicyclononene **G2** (2.23 g, 3.72 mmol), {2-[3-(*tert*-butyldimethylsilyloxy)propoxy]-3-methyl-pyridin-4-ylmethyl}cyclopropyl-amine (1.96, 5.59 mmol), DIPEA (2.55 mL, 14.9 mmol), DMAP (114 mg, 0.93 mmol), HOBt (757 mg, 5.59 mmol) and EDC·HCl (2.51 g, 13 mmol) in CH₂Cl₂ (50 mL) was stirred at rt overnight. The mixture was diluted with more CH₂Cl₂, and washed with aq. 1M HCl (3x) and aq. sat. NaHCO₃ (1x). The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound (2.16 g, 62%).

25

Examples

Example 1

(rac.)-(1*R, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide**

Bicyclononene **H1** was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂ and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

Example 2

10

(rac.)-(1R*, 5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide

15 Bicyclononene **H2** was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂ and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

Example 3

25 **(rac.)-(1R*, 3R*, 5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide**

30 Bicyclononene **H3** was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂

and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

5 Example 4

(rac.)-(1*R, 3*R**, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide**

10

Bicyclononene **H4** was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂ and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

15

Example 5

20

(rac.)-(1*R, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide**

25

Bicyclononene **H5** (2.16 g, 2.32 mmol) was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂ and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

30

Example 6

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3 λ ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-
5 (3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide

Bicyclononene **H6** (2.16 g, 2.22 mmol) was diluted with CH₂Cl₂ (10 mL) and the mixture was cooled to 0 °C. HCl (4M in dioxane, 10 mL) was added and the mixture was stirred for 1 h at 0 °C, then 1 h at rt. The solvents were removed
10 under reduced pressure and the residue was dried under high vacuum. The residue was diluted with CH₂Cl₂ and washed with aq. 1M NaOH until the org. phase had a pH > 9. The org. extracts were dried over MgSO₄, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC yielded the title compound.

15

Inhibition of human recombinant renin by the compounds of the invention

The enzymatic in vitro assay was performed in 384-well polypropylene plates (Nunc). The assay buffer consisted of 10 mM PBS (Gibco BRL) including 1 mM
20 EDTA and 0.1% BSA. The incubates were composed of 50 μ L per well of an enzyme mix and 2.5 μ L of renin inhibitors in DMSO. The enzyme mix was premixed at 4°C and consists of the following components:

- human recombinant renin (0.16 ng/mL) • synthetic human angiotensin(1-14) (0.5
25 μ M)
- hydroxyquinoline sulfate (1 mM)


The mixtures were then incubated at 37°C for 3 h.

To determine the enzymatic activity and its inhibition, the accumulated Ang I was detected by an enzyme immunoassay (EIA) in 384-well plates (Nunc). 5 μ L of the
30 incubates or standards were transferred to immuno plates which were previously coated with a covalent complex of Ang I and bovine serum albumin (Ang I – BSA). 75 μ L of Ang I-antibodies in assay buffer above including 0.01% Tween 20

were added and a primary incubation made at 4 °C overnight. The plates were washed 3 times with PBS including 0.01% Tween 20, and then incubated for 2 h at rt with an antirabbit-peroxidase coupled antibody (WA 934, Amersham). After washing the plates 3 times, the *peroxidase substrate* ABTS (2,2'-azino-di-(3-ethyl-
5 benzthiazolinsulfonate), was added and the plates incubated for 60 min at room temperature. After stopping the reaction with 0.1 M citric acid pH 4.3 the plate was evaluated in a microplate reader at 405 nm. The percentage of inhibition was calculated of each concentration point and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% (IC₅₀). The IC₅₀-values
10 of all compounds tested are below 100 nM. However selected compounds exhibit a very good bioavailability and are metabolically more stable than prior art compounds.

Claims

1. Compounds of the general formula I



General formula I

wherein

X represents -O-; -S-; -SO-; -SO₂-;

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in *meta* or *para* position;

V represents a bond; -(CH₂)_r-; -A-(CH₂)_s-; -CH₂-A-(CH₂)_t-; -(CH₂)_s-A-; -(CH₂)₂-A-(CH₂)_u-; -A-(CH₂)_v-B-; -CH₂-CH₂-CH₂-A-CH₂-; -A-CH₂-CH₂-B-CH₂-; -CH₂-A-CH₂-CH₂-B-; -CH₂-CH₂-CH₂-A-CH₂-CH₂-; -CH₂-CH₂-CH₂-CH₂-A-CH₂-; -A-CH₂-CH₂-B-CH₂-CH₂-; -CH₂-A-CH₂-CH₂-B-CH₂-; -CH₂-A-CH₂-CH₂-CH₂-B-; -CH₂-CH₂-A-CH₂-CH₂-B-; -O-CH₂-CH(OCH₃)-CH₂-O-; -O-CH₂-CH(CH₃)-CH₂-O-; -O-CH₂-CH(CF₃)-CH₂-O-; -O-CH₂-C(CH₃)₂-CH₂-O-; -O-CH₂-C(CH₃)₂-O-; -O-C(CH₃)₂-CH₂-O-; -O-CH₂-CH(CH₃)-O-; -O-CH(CH₃)-CH₂-O-; -O-CH₂-C(CH₂CH₂)-O-; or -O-C(CH₂CH₂)-CH₂-O-;

A and B independently represent -O-; -S-; -SO-; -SO₂-;

U represents aryl; heteroaryl;

T represents $-\text{CONR}^1-$; $-(\text{CH}_2)_p\text{OCO}-$; $-(\text{CH}_2)_p\text{N}(\text{R}^1)\text{CO}-$; $-(\text{CH}_2)_p\text{N}(\text{R}^1)\text{SO}_2-$; or $-\text{COO}-$;

Q represents lower alkylene; lower alkenylene;

5

M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl;

R^1 represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

10

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

15

u is the integer 1, 2, or 3;

v is the integer 2, 3, or 4;

and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of
20 diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

2. Compounds of general formula I according to claim 1 wherein X, W, V, and U are as defined in general formula I and

25

T represents $-\text{CONR}^1-$;

Q represents methylene;

M represents aryl, heteroaryl;

30 and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of

diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

3. Compounds of general formula I according to claim 1 wherein X, W, U, T, Q,
5 and M are as defined in general formula I and

V represents $-\text{CH}_2\text{CH}_2\text{O}-$; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$; $-\text{OCH}_2\text{CH}_2\text{O}-$;

- and optically pure enantiomers, mixtures of enantiomers such as racemates,
10 diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

4. Compounds of general formula I according to claim 1 wherein X, V, U, T, Q,
15 and M are as defined in general formula I and

W represents a 1,4-disubstituted phenyl group;

- and optically pure enantiomers, mixtures of enantiomers such as racemates,
20 diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

5. Compounds of general formula I according to claim 1 wherein X, W, V, Q, T,
25 and M are as defined in general formula I and

U is a mono-, di-, or trisubstituted phenyl or heteroaryl, whereby the substituents are halogen, lower alkyl, lower alkoxy, CF_3

- and optically pure enantiomers, mixtures of enantiomers such as racemates,
30 diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of

diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

6. The compounds according to any one of claims 1 to 5 selected from the group
5 consisting of

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

10

(*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide,

- 15 (*rac.*)-(1*R**, 3*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

- 20 (*rac.*)-(1*R**, 3*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide,

- 25 (*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide, and

- 30 (*rac.*)-(1*R**, 5*S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.

30

7. Pharmaceutical compositions containing at least one compound of any ones of claims 1 to 6 and usual carrier materials and adjuvants for the treatment or

prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.

8. A method for the treatment or prophylaxis of diseases which are related to the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases which are related to the RAS, which method comprises administering a compound according to any one of claims 1 to 6 to a human being or animal.

9. The use of compounds according to any one of claims 1 to 6 for the treatment or prophylaxis of diseases which are associated with the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.

10. The use of one or more compounds of any one of claims 1 to 6 in combination with other pharmacologically active compounds comprising ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics,

beta-adrenergic antagonists, alpha-adrenergic antagonists, and neutral endopeptidase inhibitors, for the treatment of disorders as set forth in any one of claims 7 to 10.

INTERNATIONAL SEARCH REPORT

In national Application No
PCT/EP2004/004371

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P9/00 A61K31/5386 A61K31/547 C07D513/08 C07D498/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/09311 A (HOFFMANN LA ROCHE) 13 March 1997 (1997-03-13) claims 1-25	1-10
A	US 3 509 161 A (DOLD OTTO ET AL) 28 April 1970 (1970-04-28) column 8, lines 1-65	1-10
A	CHEN, ZHENGMING ET AL: "Synthesis and Dopamine Transporter Affinity of 2-(Methoxycarbonyl)-9-methyl-3-phenyl-9-az abicyclo[3.3.1]nonane Derivatives" JOURNAL OF MEDICINAL CHEMISTRY, 39(24), 4744-4749 CODEN: JMCMAR; ISSN: 0022-2623, 1996, XP002291893 the whole document	1-10

-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 September 2004

Date of mailing of the international search report

01/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schuemacher, A

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.
PCT/EP2004/004371

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 03/093267 A1 (ACTELION PHARMACEUTICALS LTD., SWITZ.) 13 November 2003 (2003-11-13) claims 1-12 -----	1-10
P,Y	WO 2004/002957 A (REMEN LUBOS ; WELLER THOMAS (CH); BUR DANIEL (CH); FISCHLI WALTER (CH)) 8 January 2004 (2004-01-08) claims 1-10 -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/004371

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/004371

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9709311	A	13-03-1997	AT 242213 T	15-06-2003
			AU 708616 B2	05-08-1999
			AU 6743296 A	27-03-1997
			BR 9610385 A	06-07-1999
			CA 2230931 A1	13-03-1997
			CN 1202152 A	16-12-1998
			CZ 9800684 A3	14-10-1998
			DE 59610509 D1	10-07-2003
			DK 863875 T3	01-12-2003
			WO 9709311 A1	13-03-1997
			EP 0863875 A1	16-09-1998
			ES 2201192 T3	16-03-2004
			HU 9900926 A2	28-09-1999
			IL 123293 A	24-06-2003
			JP 11500447 T	12-01-1999
			MA 23967 A1	01-04-1997
			NO 980954 A	28-04-1998
			NZ 315677 A	28-02-2000
			PL 325425 A1	20-07-1998
			PT 863875 T	31-10-2003
			RU 2167865 C2	27-05-2001
			TR 9800409 T1	21-05-1998
			TW 474932 B	01-02-2002
			US 6051712 A	18-04-2000
			US 6150526 A	21-11-2000
			ZA 9607424 A	07-03-1997
US 3509161	A	28-04-1970	NONE	
WO 03093267	A1	13-11-2003	NONE	
WO 2004002957	A	08-01-2004	WO 2004002957 A1	08-01-2004

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.